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OBJECTIVES: Despite the ﬂexibility of Discrete-Event-Simula-
tion it is rarely used in decision analytic modelling in health care.
To illustate the beneﬁts of applying this modelling approach,
treatment allocation strategies for patients with cardiovascular
disease are evaluated. This methodological study demonstrates
how capacity constraints effect cost-effectiveness and additional
parameters for decision-making. METHODS: Cost-effectiveness
analysis is usually done for separate patient subgroups assuming
unrestricted availability of capacities, or the capacity constrain-
sts are incorporated addressing only ﬁxed waiting times.
However, in “real-world” application, a successful new treat-
ment given to only one subgroup of patients can inﬂuence the
whole patient cohort over time. For example, when medical
advances reduce the need for repeated interventions and proce-
dures, it increases available capacity. Newly developed drug-
eluting stents (DES) show promising reductions in repeated
revascularizations in speciﬁc cohorts (i.e. diabetics). Treatment
allocation strategies or guidelines determine which patients will
receive DES versus the alternative bare-metal stents (BMS). A
Discrete-Event-Simulation is used to estimate the outcome of
treatment allocation strategies for cardiovascular disease includ-
ing the long-term costs and effects of the procedures, utilization
factors and budgetary information. The simulation assumes
several capacity restrictions and takes into account daily patient
arrivals and how they effect the system as a whole. RESULTS:
In the stent simulation, a hypothetical capacity limitation for car-
diovascular intervention changes the ranking of efﬁcient treat-
ment strategies in such a way that certain strategies become
dominated. Therefore, these treatment options should not be
taken into consideration. Furthermore, evaluating treatment
strategies has the advantage of generating not only cost-effec-
tiveness outcomes but also utilization and budgetary impact
within the same simulation. CONCLUSIONS: Discrete-Event-
Simulation provides a wide range of multiple perspective out-
comes. In comparison to Markov and Decision-tree models,
capacities can be explicitly incorporated. This can change the rel-
ative cost- effectiveness results and has signiﬁcant impact on
decision-making.
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TOWARDS A MODELLED ECONOMIC EVALUATION TO
IDENTIFY THE OPTIMAL POPULATION FOR SCREENING OF
CORONARY ARTERY DISEASE
Tilden D1, Pascoe K1, Higashi MK2, Marelli C3, Kennedy L3,
Scheijbeler H1, Aristides M1
1IMS, London, UK, 2GE Healthcare, Wauwatosa, WI, USA, 3GE
Healthcare, Buckinghamshire, UK
OBJECTIVES: Currently, only symptomatic patients are
screened for CAD, leaving those asymptomatic but at risk
patients unscreened and therefore unaware of their disease
burden. Improved asymptomatic screening is an area of unmet
medical need, given that 50% of CAD patients present with a
myocardial infarction as their ﬁrst symptom. Our objective was
to develop an epidemiological and economic model to describe
the cost-effectiveness of screening for coronary artery disease in
at-risk populations. METHODS: A Markov microsimulation
model was developed to compare CAD screening strategies for
asymptomatic patients. The screening algorithm is deﬁned based
on its ability to risk stratify the population as measured by the
area under the receiver operating characteristic curve. The struc-
ture of the economic model links three main hypotheses: 1)
screening for CAD provides improved risk stratiﬁcation; 2);
which leads to initiation of effective and cost-effective interven-
tions; and 3) effective interventions reduce the burden of CAD.
Outcomes are measured as incidence of major adverse cardio-
vascular events (MACE). The population in the model is deﬁned
according to age, sex, diabetes status and ethnicity. The eco-
nomic model can be calculated for a population with any com-
bination of these risk factors. RESULTS: On the basis of United
States CAD registry data, the model identiﬁed segments of the
population with the highest incidence of CAD and therefore with
the greatest capacity to beneﬁt from CAD screening. These seg-
ments are deﬁned according to observable risk factors meaning
they can be used to identify a population eligible for CAD screen-
ing. CONCLUSIONS: Screening for CAD has the potential to
reduce disease burden and save lives. The model may be a useful
tool to 1) improve risk stratiﬁcation techniques for asympto-
matic screening; 2) identify populations where screening may be
cost-effective; and 3) identify areas where clinical data is needed
to support model validation.
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OBJECTIVE: To identify and characterize subclasses of patients
with dyslipidemia in a nationally representative sample using
Latent Class Analysis (LCA). METHODS: Dyslipidemia patients
were identiﬁed from a national database of electronic medical
records containing diagnosis, lab and medication information in
primary care setting from 1997 to 2004. LCA was applied to
patient classiﬁcation based on patient demographics, biomarker
measures (low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), total cholesterol (TC),
and triglyceride (TG)), and pre-existing coronary heart disease
(CHD), diabetes and hypertension. RESULTS: There were
72,533 patients included in this analysis. All information indices
and Lo-Mendell-Rubin test consistently suggested that a 5-class
model ﬁt the data best. Patients were classiﬁed into one of the
ﬁve classes with sizes of 17.7%, 9.6%, 29.4%, 32.6% and
10.8%, respectively. Patients in Class 1 were featured with
34.4% of HDL-C and 39.5% of TG abnormalities and high
prevalence of CHD (29.6%), diabetes (31.5%), and hyperten-
sion (78.2%). Patients in Class 2 shared similar lipid-proﬁle as
those in Class 1, but smaller percent of them carried co-mor-
bidities. Classes 3 and 4 were dominated by those with high
LDL-C and TC, but higher percent of patients in Class-3 had co-
morbidities. Class 5 was characterized by patients with abnor-
malities for all four biomarkers (80.0% for LDL-C, 76.8% for
HDL-C; 99.4% for TC, and 81.4% for TG). Patients in Classes
1 and 3 were more likely on antidyslipidemics at diagnosis, sug-
gesting that co-morbid CHD, diabetes and hypertension are
strong predictors of pharmacotherapy in primary care setting.
CONCLUSIONS: LCA appears to offer a useful approach to
studying case-mix of patients with dyslipidemia by classifying
patients into clinically similar sub-groups, which might provide
better insights to understand unmet needs and identify ap-
propriate treatment options. Our ﬁndings suggest that co-
